Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.

Shanghai Bode Gene Development Co., Ltd., established on 1998-03-22, Business scope includes bioengineering,Technology transfer in the field of genetic engineering expertise,technology development,technical consulting,Technical services and manufacture of related reagents and equipment,Sales;Bioengineering and Genetic Engineering Products,electronics,Chemical Products(In addition to dangerous goods)import and export business. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Black Technology (Wuhan) Co., Ltd., established on 2015-10-22, The scope of business includes the research and development of metabolic marker detection methods,Technical Services,technical consulting,technology transfer;Research and development of laboratory reagents,Sales(Does not contain drugs and dangerous goods);computer software,Database development,Sales.(Does not include the scope of state restrictions or prohibitions on the operation of foreign-invested enterprises)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Metanomics Health GmbH engages in providing biotechnology services. Its products include MxP broad profiling, MxP targeted profiling, MxP istope tracer, MxP biofluids quality control and diagnostic prototype assays. The company was founded in 2003 and is headquartered in Berlin, Germany.

Weifang Keneng Biotechnology Co., Ltd., established on 2011-11-01, Business scope includes production,Sell ​​Feed Additives;biotechnology research,research and development,transfer;Sales:biological feed,additive premixed feed,Feed additives;Import and export of goods permitted by the state.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Mass Spectrometry Biotechnology Co., Ltd., established on 2016-03-25, Business scope includes biological products,Pharmaceutical Intermediates,Research and development of diagnostic reagents,technology transfer;medical instruments,Production of medical supplies,Wholesale and retail;drug research,manufacture,Clinical Laboratory Services,diagnostic technology,development of medical technology,Serve,consult,Invest with own funds(Not approved by financial regulators,Not to engage in deposit taking,financing guarantee,Financial services such as wealth management on behalf of clients),Import and export business of goods and technology,Business Consulting Management,Computer software technology development,Technical Services,Computer Information System Maintenance,Laboratory equipment and consumables,Research and development of instruments and spare parts,Production,Sales,Install,repair,maintenance,Leasing and related technology development,technology transfer,technical consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.

Suntory Holdings Ltd. operates as a holding company with interests in the production and distribution of alcoholic and non-alcoholic beverages, health, beauty, and processed food products. Its services include formulation and promotion of group wide management strategies and corporate functions; sale of alcoholic beverages such as whiskey, beer, and wine; soft drinks; and other beverages such as tea and canned coffee. The company was founded by Shinjiro Torii in 1899 and is headquartered in Osaka, Japan.

Shanghai Borong Gene Development Co., Ltd., established on 1999-06-15, Business scope includes technology development in the field of genetic engineering,technology transfer,technical consulting,Technical Services,production of related products,for,pin.

Luliang Baijia Yikang Biotechnology Co., Ltd., established on 2018-06-14, Business scope includes licensed projects:Feed additive production;fertilizer production;feed production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Feed Additive Sales;Bio-feed R&D;Compound processing of soil and fertilizer;fertilizer sales;Bio-organic fertilizer research and development;Research and development of compound microbial fertilizer;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Feed Raw Material Sales;Fermentation process optimization technology research and development;R&D of industrial enzyme preparations;General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Beijing Hemei Kesheng Biotechnology Co., Ltd., established on 2011-05-17, Business scope includes biotechnology development,technical consulting,technology transfer;Sales of food additives,daily necessities,feed;acting,Place an ad;Import and export,Technology Import and Export;Production of lactic acid bacteria powder(Not produced in Beijing);sell food.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of functional sugar alcohols and starch sugar products. Its products include xylitol, sorbitol, maltitol, xylose, L-arabinose, and fructose syrup. The company was founded on July 10, 2001 and is headquartered in Quzhou, China.

Wilmar (Shanghai) Biotechnology R&D Center Co., Ltd., established on 2002-12-10, The business scope includes research and development of enzymes and enzyme preparations and application technologies,Research and development of biopesticide products,Processing of edible oil and other fats and oils,R&D of Applied Technology,plant,Research and development of deep processing technology of agricultural and sideline products and related products,food additives,Food Safety and Other Related Foods,Beverage research and development,Research and development of bioenergy technology and related products,Transfer of own technological achievements,And provide technical consultation and services related to the above business;Provide services for group investment companies and affiliated companies(rental oil tank,storehouse,office building,Industrial Facility Maintenance,sewage treatment,Logistic support, etc.)and related management.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Yunpu Kang (Dalian) Biotechnology Co., Ltd., established on 2020-06-04, Business scope includes licensed projects:Internet hospital services relying on physical hospitals,Sales of formula food for special medical purposes(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class II Medical Devices,Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Medical Research and Experimental Development,Engineering and Technology Research and Experimental Development,Sales of Class I Medical Devices,software development,software sales,Artificial intelligence application software development,Experimental analysis instrument sales,Biochemical product technology research and development,Specialty Chemicals Sales(Free of Hazardous Chemicals),Conference and Exhibition Services,Health Consulting Services(Does not include medical services),Information Consulting Service(Not including licensing information consulting services)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma

Chengdu Yiping Pharmaceutical Technology Development Co., Ltd., established on 2003-06-05, The scope of business includes the transfer of new drug research technology achievements;Transfer of new medical materials research technology achievements;Healthy food,Food research technology transfer,technical consulting;Sales:Chemical Products(Does not contain dangerous goods),Healthy food,food;disinfectant(Does not contain dangerous goods)development and sales of.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).